Overview

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
An early phase 1 for pediatric patients with recurrent or progressive CNS malignancies
Phase:
Early Phase 1
Details
Lead Sponsor:
SynerGene Therapeutics, Inc.
Treatments:
Bevacizumab
Irinotecan
Temozolomide